M

Manavata Clinical Research Institute | HCG Manavata Cancer Centr

Research site
(Unclaimed)
Location
Behind Shivang Auto, Mumbai naka Nashik- 422002, Nashik, Maharashtra, India
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

13 of 18
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania)

This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have rec...

Enrolling
Breast Cancer
Drug: Trastuzumab Emtansine
Drug: Placebo
Locations recently updated

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling
Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib

An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced lymphomas will be done to assess AUR108 safety, tolerability, p...

Enrolling
Relapsed Advanced Lymphomas
Drug: AUR108

This is first in human (FIH) study to a) evaluate the safety and tolerability profile of GRC54276, b) determine the maximum tolerated dose (MTD) and...

Enrolling
Advanced Solid Tumor
Lymphoma
Drug: GRC 54276 + Pembrolizumab
Drug: GRC 54276 + Atezolizumab

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cance...

Enrolling
Breast Neoplasms
Drug: Letrozole
Drug: Tamoxifen

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaci...

Enrolling
Neoplasm Metastasis
Breast Neoplasms
Drug: Exemestane
Drug: Imlunestrant

The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of...

Enrolling
Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis
Drug: Pemetrexed
Drug: LY3537982

The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with...

Active, not recruiting
Medullary Thyroid Cancer
Drug: Selpercatinib
Drug: Vandetanib

The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in particip...

Enrolling
Carcinoma, Non-Small-Cell Lung
Drug: Placebo
Drug: Selpercatinib

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Enrolling
Advanced Breast Cancer
Drug: Fulvestrant
Drug: ARV-471

This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a p...

Active, not recruiting
Solid Tumors Harboring NTRK Fusion
Drug: BAY2757556 (Larotrectinib, Vitrakvi)

In the SAMSON-2 study, the proposed biosimilar HD204 will be compared to its reference product EU-licensed Avastin®. The aim of the study is to demon...

Active, not recruiting
Non-small Cell Lung Cancer
Lung Cancer
Drug: Bevacizumab
Drug: Carboplatin

This multicenter prospective study will evaluate the safety and efficacy of Avastin (bevacizumab) in routine clinical practice in patients with advan...

Active, not recruiting
Ovarian Neoplasms
Fallopian Tube Neoplasms
Drug: Bevacizumab

Trial conditions

Breast Cancer (6 trials)
Cancer (4 trials)
Non-Small-Cell Lung Carc... (4 trials)
Neoplasm Metastasis (3 trials)
Lung Cancer (2 trials)
Lymphoma (2 trials)
Ovarian Epithelial Carci... (2 trials)
Ovarian Cancer (2 trials)
Carcinoma (1 trial)
Fallopian Tube Cancer (1 trial)

And 7 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems